Investigators reported construction of linked PBPK models for rosuvastatin and ticagrelor using PK-Sim. The authors used clinical pharmacokinetic data from healthy adults, elderly cohorts, and groups stratified by ABCG2 c.421C>A genotype to fit and validate the models. Key parameters were adjusted during development — including BCRP catalytic activity and documented, age-dependent declines in CYP2C9 and CYP3A4 — to better reflect physiology across the populations studied. The interaction mechanism in the model represented competitive inhibition of BCRP (ABCG2) by ticagrelor, consistent with the transporter-mediated increase in rosuvastatin exposure observed clinically. The team reported that overall predictive performance was good across the validation datasets they used.
Short statement of scope. This analysis is model-based; the manuscript is a preprint and has not undergone peer review. The authors also noted that the underlying data can be provided on reasonable request, but the source did not include new prospective clinical outcome data.
The study team ran steady-state simulations of rosuvastatin plasma exposure while co-administered with ticagrelor. They simulated dose-reduction scenarios — namely half and quarter standard doses — and compared resulting exposures using an exposure-matching approach. Reported simulated AUC fold changes were provided for specific population/genotype combinations. For young adults with the wild-type ABCG2 genotype, halving the rosuvastatin dose produced an AUC fold change of 1.44. For young adults homozygous for the c.421C>A variant, a half-dose produced an AUC fold change of 0.78, which the authors interpreted as comparable exposure in that subgroup.
Age altered the predicted magnitude of the interaction. In elderly individuals carrying the wild-type allele, a four-fold reduction in rosuvastatin dose (quarter dose) yielded an AUC fold change of 1.06. Elderly carriers of the homozygous ABCG2 variant required a smaller reduction by comparison: a half-dose in that subgroup produced an AUC fold change of 1.12. The investigators therefore reported differential effects driven by both age-related pharmacokinetic change and genotype-specific transporter activity.
The authors used exposure matching as the decision rule for proposed dose adjustments rather than safety-endpoint thresholds. Under that framework, modeled dose reductions brought predicted rosuvastatin exposure closer to reference values for each age-genotype subgroup. The reported outputs imply the following model-based dosing strategies during ticagrelor co-administration, according to the manuscript: halve the rosuvastatin dose for young wild-type or young variant carriers in the scenarios tested; halve the dose for elderly variant carriers; reduce to one quarter of the usual dose for elderly wild-type individuals to achieve exposure parity.
The manuscript did not provide stepwise clinical protocols, nor did it report prospective safety or efficacy data tied to these simulated regimens. Investigators framed these suggestions as model-based predictions to minimise potential toxicity related to increased exposure when BCRP is inhibited.
The authors explicitly stated the work is a preprint and has not been peer-reviewed; they cautioned that the findings should not be used to change clinical practice. The source did not report new clinical outcome or safety event data, nor did it provide trial-level evidence to confirm clinical benefit or reduced adverse events from the proposed dose adjustments. Details such as exact dosing schedules beyond the half and quarter scenarios, real-world adherence considerations, and patient-level covariate distributions were not provided in the preprint. The manuscript noted that all produced data are available upon reasonable request to the authors.
Investigators did not claim regulatory clearance or clinical guideline endorsement for the dosing strategies; they described PBPK outputs intended to inform further evaluation. Open questions remain and include prospective validation in clinical cohorts, safety monitoring of rhabdomyolysis risk under adjusted regimens, and integration of genotype testing into routine decision-making pathways. Those items represent the next practical steps implied by the modelling work but were not reported as completed in the source.
Ethical and disclosure notes. The authors declared no competing interests and confirmed adherence to relevant ethical reporting standards. The reader should treat the PBPK predictions as hypothesis-generating and await peer review and prospective clinical validation before altering prescribing practice.